crofelemer — Full data
H2 2026
During the second half of 2026, the Company will submit clinical study report (CSR).Source filing
JAGX biotech catalysts & pipeline
JAGUAR HEALTH INC · Data as of 2026-10-25
Upcoming catalysts
crofelemer — NDA/BLA submission
H2 2026
In the second half of 2026, based on discussions with the FDA in May 2025, the company plans to submit to the FDA the final clinical study report (CSR) for the OnTarget trial together with additional details of the responder analysis in the cohort of breast cancer patients, along with a patient survey evaluating clinically meaningful reductions in the frequency of weekly loose/watery stools for patients metastatic cancer patients receiving targeted therapies with or without standard chemotherapy.Source filing
crofelemer — NDA/BLA submission
mid-2027
Jaguar's intestinal failure program is expected to continue to provide clinical milestones, including a planned New Drug Application (NDA) filing for crofelemer for MVID in mid-2027.Source filing